AR

Amruthur Ranganatha Hemanth Kumar

Active Director Director DIN 11206069
DIN 11206069 First appointment Jul 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Amruthur Ranganatha Hemanth Kumar

Data last updated:

Amruthur Ranganatha Hemanth Kumar is a Director at Akihiro Pharmaceuticals Private Limited (since 2025). The company operates in Paper.

DIN 11206069
Primary Designation Director
Industry Paper
First Appointment 23 Jul 2025
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Jul 20252024Active

Board colleagues of Amruthur Ranganatha Hemanth Kumar

Directorship timeline

Open interactive timeline →
Akihiro Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Amruthur Ranganatha Hemanth Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amruthur Ranganatha Hemanth Kumar

Amruthur Ranganatha Hemanth Kumar currently holds 1 directorship: Akihiro Pharmaceuticals Private Limited (Director, since 23 Jul 2025).

Amruthur Ranganatha Hemanth Kumar was first appointed on 23 Jul 2025 as Director at Akihiro Pharmaceuticals Private Limited.

The current boards of Amruthur Ranganatha Hemanth Kumar's companies include Girish Basavaraju (Akihiro Pharmaceuticals Private Limited), Thuraganur Mahadevu Manjunath (Akihiro Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available